These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19140003)

  • 1. Experience of the out-patient use of memotropil in the treatment of cognitive disorders in patients with chronic progressive cerebrovascular disorders.
    Batysheva TT; Bagir' LV; Kostenko EV; Artemova IY; Vdovichenko TV; Ganzhula PA; Zhuravleva EY; Ismailov AM; Lisenker LN; Nesterova OV; Otcheskaya OV; Rotor LD; Khozova AA; Boiko AN
    Neurosci Behav Physiol; 2009 Feb; 39(2):193-7. PubMed ID: 19140003
    [No Abstract]   [Full Text] [Related]  

  • 2. [The use of memotropil for treatment of mild cognitive impairment in out-patients with progressive chronic cerebrovascular disorders].
    Batysheva TT; Bagir' LV; Kostenko EV; Artemova IIu; Bdovichenko TV; Gazhula PA; Zhuravleva EIu; Ismailov AM; Lisenker LN; Nesterova OV; Otcheskaia OV; Rotor LD; Khozova AA; Boĭko AN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(1):40-44. PubMed ID: 18689009
    [No Abstract]   [Full Text] [Related]  

  • 3. [The use of lucetam for improvement of cognitive functions in chronic cerebrovascular insufficiency (clinical and encephalographic study)].
    Bugrova SG; Novikov AE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(4):44-8. PubMed ID: 18379503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin.
    Neznamov GG; Teleshova ES
    Neurosci Behav Physiol; 2009 Mar; 39(3):311-21. PubMed ID: 19234797
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of piracetam on cognitive performance in patients undergoing bypass surgery.
    Uebelhack R; Vohs K; Zytowski M; Schewe HJ; Koch C; Konertz W
    Pharmacopsychiatry; 2003 May; 36(3):89-93. PubMed ID: 12806565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin].
    Neznamov GG; Teleshova ES
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):33-42. PubMed ID: 18697252
    [No Abstract]   [Full Text] [Related]  

  • 7. Cerebroprotective effect of piracetam in patients undergoing open heart surgery.
    Holinski S; Claus B; Alaaraj N; Dohmen PM; Neumann K; Uebelhack R; Konertz W
    Ann Thorac Cardiovasc Surg; 2011; 17(2):137-42. PubMed ID: 21597409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?
    Visser PJ; Scheltens P; Verhey FR
    J Neurol Neurosurg Psychiatry; 2005 Oct; 76(10):1348-54. PubMed ID: 16170074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute treatment of stroke. PASS group. Piracetam Acute Stroke Study.
    De Deyn PP; Orgogozo JM; De Reuck J
    Lancet; 1998 Jul; 352(9124):326. PubMed ID: 9690444
    [No Abstract]   [Full Text] [Related]  

  • 10. Piracetam: a review of pharmacological properties and clinical uses.
    Winblad B
    CNS Drug Rev; 2005; 11(2):169-82. PubMed ID: 16007238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of piracetam in cognitive impairment: a meta-analysis.
    Waegemans T; Wilsher CR; Danniau A; Ferris SH; Kurz A; Winblad B
    Dement Geriatr Cogn Disord; 2002; 13(4):217-24. PubMed ID: 12006732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NeuroAiD II (MLC901) in vascular cognitive impairment study (NEURITES).
    Chen CL; Ikram K; Anqi Q; Yin WT; Chen A; Venketasubramanian N;
    Cerebrovasc Dis; 2013; 35 Suppl 1():23-9. PubMed ID: 23548916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piracetam improves cognitive deficits caused by chronic cerebral hypoperfusion in rats.
    He Z; Liao Y; Zheng M; Zeng FD; Guo LJ
    Cell Mol Neurobiol; 2008 Jun; 28(4):613-27. PubMed ID: 17710536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Piracetam on Friedreich Ataxia.
    Elmal AD; Gündüz A; Uzun N; Apaydn H; Kzltan G
    Clin Neuropharmacol; 2016; 39(3):159-60. PubMed ID: 27171570
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances in vascular cognitive impairment.
    Bowler JV; Gorelick PB
    Stroke; 2009 May; 40(5):e315-8. PubMed ID: 19359630
    [No Abstract]   [Full Text] [Related]  

  • 16. [State of the hemostasis system and pathogenetic therapy of circulatory encephalopathy].
    Bekuzarova MR; Burd GS; Kolesnikova TI; Iasamanova AN; Kabanov AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 1997; 97(6):35-8. PubMed ID: 11517473
    [No Abstract]   [Full Text] [Related]  

  • 17. A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury.
    El Sayed I; Zaki A; Fayed AM; Shehata GM; Abdelmonem S
    Neurosurg Rev; 2018 Apr; 41(2):427-438. PubMed ID: 27539610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group.
    De Deyn PP; Reuck JD; Deberdt W; Vlietinck R; Orgogozo JM
    Stroke; 1997 Dec; 28(12):2347-52. PubMed ID: 9412612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of piracetam on the brain-organic psychosyndrome in cerebrovascular insufficiency. Results of a double-blind study in 40 cases].
    Trabant R; Poljakovic Z; Trabant D
    Ther Ggw; 1977 Aug; 116(8):1504-21. PubMed ID: 331549
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of omaron in patients with post-stroke cognitive disorders].
    Parfenov VA; Belavina GR; Vakhnina NV; Gusev VV; Levin IaI; Markin SP; Starchina IuA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(6):41-5. PubMed ID: 19672226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.